[Treatment of the keratinizing skin disorder, psoriasis, by topical vitamin D3].
The active vitamin D(3) regulates proliferation and differentiation of epidermal keratinocytes. Although topical application of steroid has been principal therapy for psoriasis, there occurs some side effects such as skin atropy, telangiectasis, and purpura. Recently topical vitamin D(3), tacalcitol, calcipotriol, and maxacalcitol, which avoid these side effects, are widely used for psoriasis. In this review, we discussed the mechanism, effect, and side effect of topical vitamin D(3) for psoriasis.
Takahashi
Hidetoshi
H
Department of Dermatology, Asahikawa Medical College.
Iizuka
Hajime
H
D000287:Administration, Topical; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D002762:Cholecalciferol / Q000008:administration & dosage* / Q000494:pharmacology; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D015603:Keratinocytes / Q000166:cytology; D009824:Ointments; D011701:PUVA Therapy; D010766:Phosphorylation / Q000187:drug effects; D011498:Protein Precursors / Q000502:physiology; D016271:Proto-Oncogene Proteins c-myc / Q000502:physiology; D011565:Psoriasis / Q000188:drug therapy*; D011503:Transglutaminases / Q000502:physiology
D009824:Ointments; D011498:Protein Precursors; D016271:Proto-Oncogene Proteins c-myc; D002762:Cholecalciferol; C032253:involucrin; D016572:Cyclosporine; D011503:Transglutaminases; D066246:ErbB Receptors